AstraZeneca Raises R&D Targets After MedImmune Acquisition

Anglo-Swedish drug maker AstraZeneca Friday said it's raising its research and development targets, aiming to have at least three new biotech drugs in late-stage trials by 2010 as a result of the integration of MedImmune, the U.S. biotech company it acquired earlier this year.
MarketWatch